Adam Sarhan: Amgen Shares To Go Higher Following Q1 Results

Loading...
Loading...

Adam Sarhan was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick.

Amgen, Inc. AMGN shares are likely to go higher after the company posts earnings Tuesday, Adam Sarhan, chief executive of Sarhan Capital told Benzinga.

"Once the company reports, they've got a phenomenal run," Sarhan said.

"Biotech in general is in a very strong market and Amgen is one of the strongest biotechs out there," Sarhan said.

Wall Street analysts on average expect Amgen will post adjusted earnings of $2.10 a share, on revenue of $4.91 billion.

But the company has beaten expectations in three of the past four quarters, and Sarhan said the "whisper number" for the current quarter calls for earnings of $2.15 a share.

"There's a tremendous amount of expectation built into the stock," Sarhan said.

"As long as it continues to act healthy, meaning the weakness is being bought and the pullbacks are shallow, I'd have to give it the bullish benefit of a doubt and suggest it wants to go higher," Sarhan said.

Check out the full interview below:

Posted In: BiotechPreviewsExclusivesTrading IdeasGeneralAdam SarhanSarhan Capital
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...